Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TGK Therapeutics
New York, New York, United Statestga.gov.au ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
TG Therapeutics has commercialized BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the US for relapsing forms of multiple sclerosis. The company’s pipeline includes early-stage programs targeting B-cell malignancies, including a BTK inhibitor, an allogeneic CAR-T therapy targeting CD19, and a bispecific monoclonal antibody targeting both CD47 and CD19. Most pipeline assets are in Phase I clinical trials.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Monoclonal antibodySmall moleculeCAR-T cell therapyBispecific monoclonal antibody
- Industry
- Biotech
02
Partnerships
No major partnerships disclosed in provided sources.
Beyond the preview
Go deeper on TGK Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TGK Therapeutics.